Iteos Historical Balance Sheet

ITOS Stock

USD 6.50 0.02 0.31%

Trend analysis of Iteos Therapeutics balance sheet accounts such as Total Current Liabilities of 72.2 M or Total Stockholder Equity of 429.9 M provides information on Iteos Therapeutics' total assets, liabilities, and equity, which is the actual value of Iteos Therapeutics to its prevalent stockholders. By breaking down trends over time using Iteos Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Iteos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iteos Therapeutics is a good buy for the upcoming year.

Iteos Therapeutics Inventory

(8.62 Million)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

About Iteos Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Iteos Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Iteos Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Iteos Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Iteos currently owns. An asset can also be divided into two categories, current and non-current.

Iteos Therapeutics Balance Sheet Chart

At this time, Iteos Therapeutics' Short and Long Term Debt Total is comparatively stable compared to the past year. Retained Earnings Total Equity is likely to gain to about 286.5 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 17.7 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Iteos Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Iteos Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Iteos Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Iteos Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Iteos Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Iteos Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.At this time, Iteos Therapeutics' Short and Long Term Debt Total is comparatively stable compared to the past year. Retained Earnings Total Equity is likely to gain to about 286.5 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 17.7 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	30.7M	19.0M	27.2M	17.7M
Total Assets	755.0M	667.6M	687.0M	533.8M

Other Current Liab Total Assets

Iteos Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets
Total Assets		0.95	0.69	0.98	0.83	0.94	0.91	0.54	-0.79	0.7	0.88	0.79	0.71	0.44	-0.52	0.99	0.75	-0.68	0.86	0.87	0.85	0.99	0.94	0.82	0.98	0.99
Other Current Liab	0.95		0.52	0.97	0.89	0.94	0.91	0.35	-0.61	0.71	0.89	0.62	0.81	0.47	-0.62	0.91	0.66	-0.71	0.86	0.93	0.86	0.96	0.92	0.68	0.97	0.91
Total Current Liabilities	0.69	0.52		0.55	0.31	0.49	0.5	0.97	-0.92	0.5	0.35	0.92	0.14	-0.01	-0.09	0.76	0.86	-0.4	0.5	0.34	0.47	0.67	0.48	0.98	0.55	0.77
Total Stockholder Equity	0.98	0.97	0.55		0.87	0.96	0.92	0.38	-0.7	0.68	0.92	0.7	0.78	0.5	-0.56	0.96	0.65	-0.69	0.87	0.92	0.87	0.97	0.97	0.71	1.0	0.96
Other Liab	0.83	0.89	0.31	0.87		0.95	0.9	0.08	-0.34	0.54	0.91	0.34	0.97	0.62	-0.77	0.76	0.53	-0.55	0.71	0.94	0.7	0.86	0.84	0.5	0.87	0.76
Net Tangible Assets	0.94	0.94	0.49	0.96	0.95		0.91	0.28	-0.59	0.55	0.92	0.59	0.89	0.59	-0.59	0.91	0.64	-0.68	0.85	0.91	0.84	0.93	0.95	0.65	0.96	0.9
Property Plant And Equipment Net	0.91	0.91	0.5	0.92	0.9	0.91		0.32	-0.55	0.63	0.97	0.55	0.81	0.68	-0.73	0.86	0.73	-0.61	0.77	0.96	0.79	0.94	0.89	0.67	0.92	0.86
Current Deferred Revenue	0.54	0.35	0.97	0.38	0.08	0.28	0.32		-0.88	0.45	0.16	0.88	-0.1	-0.17	0.04	0.62	0.76	-0.26	0.33	0.16	0.31	0.51	0.31	0.9	0.38	0.62
Net Debt	-0.79	-0.61	-0.92	-0.7	-0.34	-0.59	-0.55	-0.88		-0.57	-0.47	-1.0	-0.16	-0.03	0.04	-0.86	-0.76	0.5	-0.63	-0.42	-0.62	-0.74	-0.64	-0.92	-0.7	-0.86
Retained Earnings	0.7	0.71	0.5	0.68	0.54	0.55	0.63	0.45	-0.57		0.63	0.57	0.37	-0.11	-0.59	0.7	0.48	-0.3	0.43	0.67	0.44	0.76	0.48	0.61	0.68	0.7
Accounts Payable	0.88	0.89	0.35	0.92	0.91	0.92	0.97	0.16	-0.47	0.63		0.48	0.84	0.67	-0.71	0.82	0.59	-0.61	0.77	0.97	0.79	0.91	0.9	0.53	0.92	0.82
Cash	0.79	0.62	0.92	0.7	0.34	0.59	0.55	0.88	-1.0	0.57	0.48		0.16	0.04	-0.04	0.86	0.76	-0.5	0.63	0.43	0.62	0.75	0.65	0.92	0.7	0.86
Non Current Assets Total	0.71	0.81	0.14	0.78	0.97	0.89	0.81	-0.1	-0.16	0.37	0.84	0.16		0.67	-0.73	0.62	0.4	-0.55	0.68	0.88	0.67	0.73	0.78	0.32	0.77	0.63
Non Currrent Assets Other	0.44	0.47	-0.01	0.5	0.62	0.59	0.68	-0.17	-0.03	-0.11	0.67	0.04	0.67		-0.43	0.35	0.37	-0.47	0.53	0.63	0.56	0.44	0.65	0.13	0.5	0.35
Other Assets	-0.52	-0.62	-0.09	-0.56	-0.77	-0.59	-0.73	0.04	0.04	-0.59	-0.71	-0.04	-0.73	-0.43		-0.43	-0.28	0.04	-0.22	-0.82	-0.24	-0.61	-0.46	-0.27	-0.56	-0.43
Cash And Short Term Investments	0.99	0.91	0.76	0.96	0.76	0.91	0.86	0.62	-0.86	0.7	0.82	0.86	0.62	0.35	-0.43		0.78	-0.67	0.84	0.8	0.83	0.97	0.91	0.87	0.96	1.0
Net Receivables	0.75	0.66	0.86	0.65	0.53	0.64	0.73	0.76	-0.76	0.48	0.59	0.76	0.4	0.37	-0.28	0.78		-0.66	0.7	0.56	0.69	0.78	0.62	0.9	0.64	0.78
Common Stock Total Equity	-0.68	-0.71	-0.4	-0.69	-0.55	-0.68	-0.61	-0.26	0.5	-0.3	-0.61	-0.5	-0.55	-0.47	0.04	-0.67	-0.66		-0.95	-0.54	-0.95	-0.66	-0.74	-0.49	-0.68	-0.67
Common Stock Shares Outstanding	0.86	0.86	0.5	0.87	0.71	0.85	0.77	0.33	-0.63	0.43	0.77	0.63	0.68	0.53	-0.22	0.84	0.7	-0.95		0.72	1.0	0.83	0.91	0.61	0.86	0.84
Non Current Liabilities Total	0.87	0.93	0.34	0.92	0.94	0.91	0.96	0.16	-0.42	0.67	0.97	0.43	0.88	0.63	-0.82	0.8	0.56	-0.54	0.72		0.73	0.91	0.87	0.54	0.91	0.8
Capital Surpluse	0.85	0.86	0.47	0.87	0.7	0.84	0.79	0.31	-0.62	0.44	0.79	0.62	0.67	0.56	-0.24	0.83	0.69	-0.95	1.0	0.73		0.83	0.91	0.59	0.86	0.83
Other Current Assets	0.99	0.96	0.67	0.97	0.86	0.93	0.94	0.51	-0.74	0.76	0.91	0.75	0.73	0.44	-0.61	0.97	0.78	-0.66	0.83	0.91	0.83		0.91	0.81	0.97	0.97
Other Stockholder Equity	0.94	0.92	0.48	0.97	0.84	0.95	0.89	0.31	-0.64	0.48	0.9	0.65	0.78	0.65	-0.46	0.91	0.62	-0.74	0.91	0.87	0.91	0.91		0.63	0.97	0.91
Total Liab	0.82	0.68	0.98	0.71	0.5	0.65	0.67	0.9	-0.92	0.61	0.53	0.92	0.32	0.13	-0.27	0.87	0.9	-0.49	0.61	0.54	0.59	0.81	0.63		0.7	0.87
Net Invested Capital	0.98	0.97	0.55	1.0	0.87	0.96	0.92	0.38	-0.7	0.68	0.92	0.7	0.77	0.5	-0.56	0.96	0.64	-0.68	0.86	0.91	0.86	0.97	0.97	0.7		0.96
Total Current Assets	0.99	0.91	0.77	0.96	0.76	0.9	0.86	0.62	-0.86	0.7	0.82	0.86	0.63	0.35	-0.43	1.0	0.78	-0.67	0.84	0.8	0.83	0.97	0.91	0.87	0.96

Click cells to compare fundamentals

Iteos Therapeutics Account Relationship Matchups

Iteos Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	344.6M	884.7M	755.0M	667.6M	687.0M	533.8M
Other Current Liab	7.5M	21.3M	30.7M	19.0M	27.2M	17.7M
Total Current Liabilities	15.0M	304.1M	42M	40.0M	40.4M	72.2M
Total Stockholder Equity	323.2M	552.8M	663.3M	575.2M	590.3M	429.9M
Other Liab	1.9M	6.4M	23.2M	45.8M	52.7M	55.3M
Net Tangible Assets	(36.1M)	323.2M	552.8M	663.3M	762.8M	801.0M
Property Plant And Equipment Net	1.4M	7.4M	6.8M	10.7M	10.0M	6.1M
Current Deferred Revenue	4.5M	281.1M	13.8M	2.1M	1.4M	1.3M
Net Debt	(336.3M)	(843.2M)	(280.1M)	(245.1M)	(137.0M)	(143.9M)
Retained Earnings	(73.9M)	140.6M	237.3M	124.6M	(9.8M)	(9.3M)
Accounts Payable	3.0M	5.1M	7.7M	11.3M	8.5M	6.0M
Cash	336.3M	848.5M	284.8M	251.2M	142.1M	135.0M
Non Current Assets Total	5.0M	10.0M	126.7M	116.9M	177.4M	186.3M
Non Currrent Assets Other	3.5M	2.3M	1.7M	5.7M	7.1M	4.1M
Other Assets	3.3M	3.7M	2.6M	1.7M	1.5M	2.2M
Cash And Short Term Investments	336.3M	848.5M	613.2M	531.9M	494.6M	450.4M
Net Receivables	325K	12.1M	2.4M	6.5M	5.9M	5.3M
Common Stock Shares Outstanding	35.0M	37.8M	37.8M	35.8M	40.5M	36.0M
Liabilities And Stockholders Equity	344.6M	884.7M	755.0M	667.6M	687.0M	533.8M
Non Current Liabilities Total	6.4M	27.8M	49.7M	52.3M	56.3M	31.7M
Other Current Assets	2.9M	14.1M	12.7M	12.2M	11.2M	8.6M
Other Stockholder Equity	396.4M	413.2M	435.7M	463.8M	616.0M	373.8M
Total Liab	21.4M	331.9M	91.7M	92.4M	96.7M	103.9M
Net Invested Capital	323.2M	552.8M	663.3M	575.2M	590.3M	417.7M
Total Current Assets	339.5M	874.7M	628.3M	550.7M	509.5M	464.0M
Accumulated Other Comprehensive Income	617K	(1.0M)	(9.6M)	(13.2M)	(16.0M)	(15.2M)
Non Current Liabilities Other	482K	480K	27.8M	49.7M	57.1M	60.0M
Net Working Capital	324.5M	570.6M	586.3M	510.6M	469.2M	391.7M
Property Plant Equipment	1.3M	1.4M	2.1M	2.1M	2.4M	1.8M
Property Plant And Equipment Gross	1.4M	10.4M	10.2M	15.1M	14.9M	10.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iteos Historical Balance Sheet

Iteos Therapeutics Inventory

(8.62 Million)

About Iteos Balance Sheet Analysis

Iteos Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Iteos Therapeutics balance sheet Correlations

Iteos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iteos Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Iteos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Capital Surpluse	+ 1.0	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Capital Surpluse	- 0.95	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.95	Common Stock Total Equity
Total Liab	- 0.92	Net Debt
Net Debt	- 0.92	Total Current Liabilities
Net Debt	- 0.88	Current Deferred Revenue